BCAX

Bicara Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality3/10
  • Growth↓ 2/10
  • Value↑ 5/10
Bicara Therapeutics sales and earnings growth
BCAX Growth
Fair
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 80.24%
  • FCF Y/Y↓ -31.97%
Bicara Therapeutics gross and profit margin trends
BCAX Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ 0.00%
Bicara Therapeutics net debt vs free cash flow
BCAX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Bicara Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks